Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander R Lyon

Showing results (211-220 of 267) with videos related to

Pageof 27
Sort By:
JACC. Cardiooncology|April 17, 2025
Quality-of-Care Measures for Cardio-Oncology: An IC-OS and ACC Cardio-Oncology Leadership Council PerspectiveVijay U Rao, Anita Deswal, Daniel Lenihan, et al.
European Journal of Heart Failure|June 28, 2019
Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathyJohann Bauersachs, Tobias König, Peter van der Meer, et al.
European Journal of Heart Failure|March 11, 2025
Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the HeartAlessandra Ghigo, Pietro Ameri, Aarti Asnani, et al.
JAMA|March 7, 2013
Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathyAnkur Gulati, Andrew Jabbour, Tevfik F Ismail, et al.
European Heart Journal|February 5, 2020
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registryJosé López-Sendón, Carlos Álvarez-Ortega, Pilar Zamora Auñon, et al.
Cancer Medicine|March 27, 2026
Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology ProvidersAbdelrahman Ali, Suparna C Clasen, Anne Blaes, et al.
Cardiovascular Research|July 20, 2020
Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the HeartCarlo Gabriele Tocchetti, Pietro Ameri, Rudolf A de Boer, et al.
European Heart Journal|December 14, 2021
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Daniel Lenihan, Saro Armenian, et al.
Journal of Cardiac Failure|May 22, 2021
Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial BiopsyPetar M Seferović, Hiroyuki Tsutsui, Dennis M Mcnamara, et al.
European Journal of Heart Failure|May 19, 2021
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsyPetar M Seferović, Hiroyuki Tsutsui, Dennis M McNamara, et al.
Pageof 27

Showing results (211-220 of 267) with videos related to

Sort By:
Pageof 27
JACC. Cardiooncology|April 17, 2025
Quality-of-Care Measures for Cardio-Oncology: An IC-OS and ACC Cardio-Oncology Leadership Council PerspectiveVijay U Rao, Anita Deswal, Daniel Lenihan, et al.
European Journal of Heart Failure|June 28, 2019
Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathyJohann Bauersachs, Tobias König, Peter van der Meer, et al.
European Journal of Heart Failure|March 11, 2025
Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the HeartAlessandra Ghigo, Pietro Ameri, Aarti Asnani, et al.
JAMA|March 7, 2013
Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathyAnkur Gulati, Andrew Jabbour, Tevfik F Ismail, et al.
European Heart Journal|February 5, 2020
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registryJosé López-Sendón, Carlos Álvarez-Ortega, Pilar Zamora Auñon, et al.
Cancer Medicine|March 27, 2026
Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology ProvidersAbdelrahman Ali, Suparna C Clasen, Anne Blaes, et al.
Cardiovascular Research|July 20, 2020
Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the HeartCarlo Gabriele Tocchetti, Pietro Ameri, Rudolf A de Boer, et al.
European Heart Journal|December 14, 2021
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Daniel Lenihan, Saro Armenian, et al.
Journal of Cardiac Failure|May 22, 2021
Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial BiopsyPetar M Seferović, Hiroyuki Tsutsui, Dennis M Mcnamara, et al.
European Journal of Heart Failure|May 19, 2021
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsyPetar M Seferović, Hiroyuki Tsutsui, Dennis M McNamara, et al.
Pageof 27